EFFECTS OF CLOFAZIMINE ANALOGS AND TUMOR-NECROSIS-FACTOR-ALPHA INDIVIDUALLY AND IN COMBINATION ON HUMAN POLYMORPHONUCLEAR LEUKOCYTE FUNCTIONS INVITRO

被引:11
作者
KRAJEWSKA, MM
ANDERSON, R
OSULLIVAN, JF
机构
[1] UNIV PRETORIA,INST PATHOL,DEPT IMMUNOL,MRC,STUDY PHAGOCYTE FUNCT RES UNIT,PRETORIA,SOUTH AFRICA
[2] NATL UNIV IRELAND UNIV COLL DUBLIN,DEPT CHEM,DUBLIN 4,IRELAND
来源
INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY | 1993年 / 15卷 / 02期
基金
英国医学研究理事会;
关键词
D O I
10.1016/0192-0561(93)90086-E
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
In the present study the individual and interactive effects of clofazimine, or three analogues of this agent (selected on the basis of similar or superior pro-oxidative properties: B669, B746 and B4021) and human recombinant TNF-alpha on the generation of antimicrobial oxidants by human polymorphonuclear leukocytes (PMNL), as well as release of granule enzymes from these cells, were investigated in vitro. All four riminophenazines at the concentrations tested (0.5 and 1.0 mug/ml) significantly increased myeloperoxidase (MPO)-mediated iodination, superoxide (O2.-) generation, oxygen (O2) consumption and chemiluminescence (CL), as well as the release of both primary and secondary granule contents (measured as the release of MPO, lysozyme and vitamin B-12-binding protein) by stimulated PMNL. Similar, but less impressive effects were observed with TNF-alpha (0.4-50.0 ng/ml). When PMNL were preincubated with both TNF-alpha and clofazimine or its analogues, the observed stimulation of cellular oxidative metabolism and granule enzyme release was at least additive in many assays. These data demonstrate that the spectrum of effects of clofazimine and its analogues on PMNL closely resemble those of TNF-alpha. Furthermore, TNF-alpha potentiates the pro-oxidative effects of clofazimine and its analogues on PMNL. Among the riminophenazines tested, clofazimine and B669 appear to be the most potent pro-oxidative agents for PMNL.
引用
收藏
页码:99 / 111
页数:13
相关论文
共 39 条
[1]   EFFECT OF COMBINED THERAPY WITH ANSAMYCIN, CLOFAZIMINE, ETHAMBUTOL, AND ISONIAZID FOR MYCOBACTERIUM-AVIUM INFECTION IN PATIENTS WITH AIDS [J].
AGINS, BD ;
BERMAN, DS ;
SPICEHANDLER, D ;
ELSADR, W ;
SIMBERKOFF, MS ;
RAHAL, JJ .
JOURNAL OF INFECTIOUS DISEASES, 1989, 159 (04) :784-787
[2]   APPARENT INVOLVEMENT OF PHOSPHOLIPASE-A2, BUT NOT PROTEIN KINASE-C, IN THE PRO-OXIDATIVE INTERACTIONS OF CLOFAZIMINE WITH HUMAN PHAGOCYTES [J].
ANDERSON, R ;
BEYERS, AD ;
SAVAGE, JE ;
NEL, AE .
BIOCHEMICAL PHARMACOLOGY, 1988, 37 (24) :4635-4641
[3]   CLOFAZIMINE-MEDIATED ENHANCEMENT OF REACTIVE OXIDANT PRODUCTION BY HUMAN PHAGOCYTES AS A POSSIBLE THERAPEUTIC MECHANISM [J].
ANDERSON, R ;
ZEIS, BM ;
ANDERSON, IF .
DERMATOLOGICA, 1988, 176 (05) :234-242
[5]  
ATKINSON YH, 1990, IMMUNOLOGY, V70, P82
[6]   INVITRO ACTIVITY OF CLOFAZIMINE AGAINST RAPIDLY GROWING NONCHROMOGENIC MYCOBACTERIA [J].
AUSINA, V ;
CONDOM, MJ ;
MIRELIS, B ;
LUQUIN, M ;
COLL, P ;
PRATS, G .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1986, 29 (05) :951-952
[7]   PRIMING OF HUMAN NEUTROPHIL FUNCTIONS BY TUMOR-NECROSIS-FACTOR - ENHANCEMENT OF SUPEROXIDE ANION GENERATION, DEGRANULATION, AND CHEMOTAXIS TO CHEMOATTRACTANTS C5A AND F-MET-LEU-PHE [J].
BAJAJ, MS ;
KEW, RR ;
WEBSTER, RO ;
HYERS, TM .
INFLAMMATION, 1992, 16 (03) :241-250
[8]  
BARRY VINCENT C., 1965, LEPROSY REV, V36, P3
[9]   THE PRESENCE OF CACHECTIN TUMOR NECROSIS FACTOR IN HUMAN-DISEASE STATES [J].
BEUTLER, B .
AMERICAN JOURNAL OF MEDICINE, 1988, 85 (03) :287-288
[10]   TREATMENT OF PUSTULAR PSORIASIS WITH CLOFAZIMINE [J].
CHUAPRAPAISILP, T ;
PIAMPHONGSANT, T .
BRITISH JOURNAL OF DERMATOLOGY, 1978, 99 (03) :303-305